Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort
E Shelton, JR Allegretti, B Stevens… - Inflammatory bowel …, 2015 - academic.oup.com
Background Vedolizumab (VDZ) demonstrated efficacy in Crohn's disease (CD) and
ulcerative colitis (UC) in the GEMINI trials. Our aim was to evaluate the efficacy of VDZ at …
ulcerative colitis (UC) in the GEMINI trials. Our aim was to evaluate the efficacy of VDZ at …
A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
HH Shim, PW Chan, SW Chuah, BJ Schwender… - JGH …, 2018 - Wiley Online Library
Recent advancement in the understanding of the pathophysiology of inflammatory bowel
disease has seen an expansion in therapeutic options. Vedolizumab, a selective α4β7 …
disease has seen an expansion in therapeutic options. Vedolizumab, a selective α4β7 …
Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab
A Hu, PG Kotze, A Burgevin, W Tan, A Jess… - Clinical …, 2021 - Elsevier
Background & Aims Patients with Crohn's disease (CD) or ulcerative colitis (UC) often
receive combination therapy with an immunomodulator and tumor necrosis factor …
receive combination therapy with an immunomodulator and tumor necrosis factor …
Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients
C Chapuis‐Biron, A Bourrier, M Nachury… - Alimentary …, 2020 - Wiley Online Library
Summary Background The management of Crohn's disease patients with perianal lesions
and anti‐TNF failure is challenging. Aims To assess the effectiveness of vedolizumab in …
and anti‐TNF failure is challenging. Aims To assess the effectiveness of vedolizumab in …
[HTML][HTML] Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative …
JG Hashash, CG Abou Fadel, HH Rimmani… - Annals of …, 2021 - ncbi.nlm.nih.gov
Despite current guidelines, the optimal treatment of patients with inflammatory bowel
disease (IBD) remains challenging. The available medications are not without risk and there …
disease (IBD) remains challenging. The available medications are not without risk and there …
Predictors of clinical response and remission at 1 year among a multicenter cohort of patients with inflammatory bowel disease treated with vedolizumab
JR Allegretti, EL Barnes, B Stevens, M Storm… - Digestive diseases and …, 2017 - Springer
Background Vedolizumab (VDZ) has demonstrated long-term efficacy in Crohn's disease
(CD) and ulcerative colitis (UC) in phase III trials. Aims Our aim was to evaluate the efficacy …
(CD) and ulcerative colitis (UC) in phase III trials. Aims Our aim was to evaluate the efficacy …
[HTML][HTML] Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with …
Background Management of inflammatory bowel disease (IBD) involves biological agents,
often in combination with thiopurines or methotrexate. The aim of our study was to compare …
often in combination with thiopurines or methotrexate. The aim of our study was to compare …
How to manage IBD in the 'elderly'
JP Segal, HMT Htet, J Limdi, BH Hayee - Frontline Gastroenterology, 2020 - fg.bmj.com
As the incidence of inflammatory bowel disease (IBD) rises and the global population ages,
the number of older people living with these conditions will inevitably increase. The …
the number of older people living with these conditions will inevitably increase. The …
[HTML][HTML] Chronic cholestatic liver injury attributable to vedolizumab
JG Stine, J Wang, BW Behm - Journal of clinical and translational …, 2016 - ncbi.nlm.nih.gov
Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an α4β7
integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory …
integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory …
Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK–a retrospective observational study
JR White, S Din, RJM Ingram, S Foley… - Scandinavian Journal …, 2020 - Taylor & Francis
Purpose Clinical trials have demonstrated efficacy of vedolizumab in ulcerative colitis (UC)
and Crohn's disease (CD). Further real-world data is needed to inform clinical practice. The …
and Crohn's disease (CD). Further real-world data is needed to inform clinical practice. The …